Literature DB >> 17303019

The use of the Acucise technique for ureteropelvic junction obstruction: a trade-off between efficacy and invasiveness?

Joyce Baard1, Theodorus M de Reijke, Jean J M C H de la Rosette.   

Abstract

Open pyeloplasty is traditionally the recommended treatment for ureteropelvic junction obstruction. In the past decades, several less invasive procedures emerged with the advantages of lower morbidity and better patient tolerance. In 1993, an electrosurgical cutting balloon device called the Acucise (Applied Medical Resources Corp., Laguna Hills, CA) was introduced. It was presented as a straightforward, safe procedure that can be performed in a complete retrograde fashion under fluoroscopic guidance. Despite these advantages; however, it is not yet a generally excepted procedure. This is mainly due to the fact that specific patient selection is needed, and success rates are comparable with other already established endoscopic procedures. Considering the large variety of minimally invasive procedures available, treatment of choice must be based on several factors such as success rate, morbidity, cost, and surgeon's experience. Acucise is considered a good alternative for the treatment of ureteropelvic junction obstruction in selected patients. However, the efficacy is significantly lower than the reference standard.

Entities:  

Mesh:

Year:  2007        PMID: 17303019     DOI: 10.1007/s11934-007-0063-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  24 in total

1.  Prospective, randomized comparison of ureteroscopic endopyelotomy using holmium:YAG laser and balloon catheter.

Authors:  Ahmed R el-Nahas; Ahmed M Shoma; Ibrahim Eraky; Mahmoud R el-Kenawy; Hamdy A el-Kappany
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

2.  Acucise endopyelotomy: a technique with limited efficacy for primary ureteropelvic junction obstruction in adults.

Authors:  Steffen Weikert; Frank Christoph; Markus Müller; Martin Schostak; Kurt Miller; Mark Schrader
Journal:  Int J Urol       Date:  2005-10       Impact factor: 3.369

3.  Endopyelotomy with the Acucise cutting balloon device. Early clinical experience.

Authors:  A Gelet; M Combe; J M Ramackers; N Ben Rais; X Martin; M Dawahra; J M Maréchal; J M Dubernard
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

4.  Endopyelotomy and endoureterotomy with the acucise ureteral cutting balloon device: preliminary experience.

Authors:  P S Chandhoke; R V Clayman; A M Stone; E M McDougall; T Buelna; N Hilal; M Chang; M J Stegwell
Journal:  J Endourol       Date:  1993-02       Impact factor: 2.942

5.  Contemporary management of ureteropelvic junction obstruction: practice patterns in Minnesota.

Authors:  Elizabeth Fallon; Barbara Ercole; Courtney Lee; Sara Best; Jason Skenazy; Manoj Monga
Journal:  J Endourol       Date:  2005 Jan-Feb       Impact factor: 2.942

6.  Endopyelotomy for primary ureteropelvic junction obstruction: risk factors determine the success rate.

Authors:  H Danuser; D K Ackermann; D Böhlen; U E Studer
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

7.  Acucise endopyelotomy: assessment of long-term durability.

Authors:  R B Nadler; G S Rao; M S Pearle; S Y Nakada; R V Clayman
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

8.  Endopyeloplasty versus endopyelotomy versus laparoscopic pyeloplasty for primary ureteropelvic junction obstruction.

Authors:  Mihir M Desai; Mahesh R Desai; Inderbir S Gill
Journal:  Urology       Date:  2004-07       Impact factor: 2.649

9.  Comparison of open and endourologic approaches to the obstructed ureteropelvic junction.

Authors:  J D Brooks; L R Kavoussi; G M Preminger; W W Schuessler; R G Moore
Journal:  Urology       Date:  1995-12       Impact factor: 2.649

10.  The role of Acucise endopyelotomy in the treatment of ureteropelvic junction obstruction.

Authors:  Chandra S Biyani; Suks Minhas; James el Cast; David J Almond; Graeme Cooksey; John W Hetherington
Journal:  Eur Urol       Date:  2002-03       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.